This HTML5 document contains 255 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00571/identifier/pharmgkb/
dctermshttp://purl.org/dc/terms/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00571/identifier/kegg-compound/
n21http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n14http://linked.opendata.cz/resource/mesh/concept/
n7http://linked.opendata.cz/resource/drugbank/company/
n33http://linked.opendata.cz/resource/drugbank/drug/DB00571/identifier/bindingdb/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00571/identifier/pubchem-compound/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n34http://linked.opendata.cz/resource/drugbank/mixture/
n12http://www.drugs.com/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00571/identifier/pubchem-substance/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00571/identifier/drugbank/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00571/identifier/iuphar/
n17http://bio2rdf.org/drugbank:
n30http://linked.opendata.cz/resource/drugbank/drug/DB00571/identifier/guide-to-pharmacology/
admshttp://www.w3.org/ns/adms#
n29http://linked.opendata.cz/resource/drugbank/drug/DB00571/identifier/national-drug-code-directory/
n25http://www.rxlist.com/cgi/generic/
n20http://linked.opendata.cz/resource/drugbank/patent/
n32http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
n13http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00571/identifier/chemspider/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00571/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00571/identifier/wikipedia/
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00571
rdf:type
n3:Drug
n3:description
A widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety. [PubChem]
n3:dosage
n6:271B4B3E-363D-11E5-9242-09173F13E4C5 n6:271B4B3F-363D-11E5-9242-09173F13E4C5 n6:271B4B3B-363D-11E5-9242-09173F13E4C5 n6:271B4B40-363D-11E5-9242-09173F13E4C5 n6:271B4B3C-363D-11E5-9242-09173F13E4C5 n6:271B4B3D-363D-11E5-9242-09173F13E4C5 n6:271B4B37-363D-11E5-9242-09173F13E4C5 n6:271B4B38-363D-11E5-9242-09173F13E4C5 n6:271B4B39-363D-11E5-9242-09173F13E4C5 n6:271B4B3A-363D-11E5-9242-09173F13E4C5 n6:271B4B45-363D-11E5-9242-09173F13E4C5 n6:271B4B41-363D-11E5-9242-09173F13E4C5 n6:271B4B42-363D-11E5-9242-09173F13E4C5 n6:271B4B43-363D-11E5-9242-09173F13E4C5 n6:271B4B44-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK: Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2007 Jun 21;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17588604 # Ohnishi ST, Sadanaga KK, Katsuoka M, Weidanz WP: Effects of membrane acting-drugs on plasmodium species and sickle cell erythrocytes. Mol Cell Biochem. 1989 Nov 23-Dec 19;91(1-2):159-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2695829 # Singh N, Puri SK: Interaction between chloroquine and diverse pharmacological agents in chloroquine resistant Plasmodium yoelii nigeriensis. Acta Trop. 2000 Nov 2;77(2):185-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11080509 # Murphy SC, Harrison T, Hamm HE, Lomasney JW, Mohandas N, Haldar K: Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med. 2006 Dec;3(12):e528. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17194200
n3:group
approved investigational
n3:halfLife
4 hours
n3:indication
For the prophylaxis of migraine.
n3:manufacturer
n7:271B4AE2-363D-11E5-9242-09173F13E4C5 n7:271B4AE3-363D-11E5-9242-09173F13E4C5 n7:271B4AE0-363D-11E5-9242-09173F13E4C5 n7:271B4AE1-363D-11E5-9242-09173F13E4C5 n7:271B4AE6-363D-11E5-9242-09173F13E4C5 n7:271B4AE7-363D-11E5-9242-09173F13E4C5 n7:271B4AE4-363D-11E5-9242-09173F13E4C5 n7:271B4AE5-363D-11E5-9242-09173F13E4C5 n7:271B4AFB-363D-11E5-9242-09173F13E4C5 n7:271B4AFC-363D-11E5-9242-09173F13E4C5 n7:271B4AF9-363D-11E5-9242-09173F13E4C5 n7:271B4AFA-363D-11E5-9242-09173F13E4C5 n7:271B4AFF-363D-11E5-9242-09173F13E4C5 n7:271B4B00-363D-11E5-9242-09173F13E4C5 n7:271B4AFD-363D-11E5-9242-09173F13E4C5 n7:271B4AFE-363D-11E5-9242-09173F13E4C5 n7:271B4AEB-363D-11E5-9242-09173F13E4C5 n7:271B4AEC-363D-11E5-9242-09173F13E4C5 n7:271B4AE8-363D-11E5-9242-09173F13E4C5 n7:271B4AE9-363D-11E5-9242-09173F13E4C5 n7:271B4AEF-363D-11E5-9242-09173F13E4C5 n7:271B4AF8-363D-11E5-9242-09173F13E4C5 n7:271B4AED-363D-11E5-9242-09173F13E4C5 n7:271B4AEE-363D-11E5-9242-09173F13E4C5 n7:271B4AF7-363D-11E5-9242-09173F13E4C5 n7:271B4AF5-363D-11E5-9242-09173F13E4C5 n7:271B4AF6-363D-11E5-9242-09173F13E4C5 n7:271B4B03-363D-11E5-9242-09173F13E4C5 n7:271B4B01-363D-11E5-9242-09173F13E4C5 n7:271B4B02-363D-11E5-9242-09173F13E4C5 n7:271B4AF0-363D-11E5-9242-09173F13E4C5 n7:271B4AF3-363D-11E5-9242-09173F13E4C5 n7:271B4AF4-363D-11E5-9242-09173F13E4C5 n7:271B4AF1-363D-11E5-9242-09173F13E4C5 n7:271B4AF2-363D-11E5-9242-09173F13E4C5 n7:271B4AEA-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00571 n32:DB00571
dcterms:title
Propranolol
adms:identifier
n9:4946 n10:46505387 n22:Propranolol n23:PA451145 n24:DB00571 n26:8499 n27:4777 n28:C07407 n29:65726-251-10 n30:564 n31:564 n33:25761
n3:mechanismOfAction
Propranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.
n3:packager
n7:271B4AA6-363D-11E5-9242-09173F13E4C5 n7:271B4ACA-363D-11E5-9242-09173F13E4C5 n7:271B4AC6-363D-11E5-9242-09173F13E4C5 n7:271B4AC9-363D-11E5-9242-09173F13E4C5 n7:271B4AC7-363D-11E5-9242-09173F13E4C5 n7:271B4AC8-363D-11E5-9242-09173F13E4C5 n7:271B4AA0-363D-11E5-9242-09173F13E4C5 n7:271B4AA1-363D-11E5-9242-09173F13E4C5 n7:271B4A9E-363D-11E5-9242-09173F13E4C5 n7:271B4A9F-363D-11E5-9242-09173F13E4C5 n7:271B4A9C-363D-11E5-9242-09173F13E4C5 n7:271B4A9D-363D-11E5-9242-09173F13E4C5 n7:271B4A9A-363D-11E5-9242-09173F13E4C5 n7:271B4A9B-363D-11E5-9242-09173F13E4C5 n7:271B4AB9-363D-11E5-9242-09173F13E4C5 n7:271B4ABA-363D-11E5-9242-09173F13E4C5 n7:271B4AB7-363D-11E5-9242-09173F13E4C5 n7:271B4AB8-363D-11E5-9242-09173F13E4C5 n7:271B4AB5-363D-11E5-9242-09173F13E4C5 n7:271B4AB6-363D-11E5-9242-09173F13E4C5 n7:271B4AB3-363D-11E5-9242-09173F13E4C5 n7:271B4AB4-363D-11E5-9242-09173F13E4C5 n7:271B4AC1-363D-11E5-9242-09173F13E4C5 n7:271B4AC2-363D-11E5-9242-09173F13E4C5 n7:271B4ABF-363D-11E5-9242-09173F13E4C5 n7:271B4AC0-363D-11E5-9242-09173F13E4C5 n7:271B4ABD-363D-11E5-9242-09173F13E4C5 n7:271B4ABE-363D-11E5-9242-09173F13E4C5 n7:271B4ABB-363D-11E5-9242-09173F13E4C5 n7:271B4ABC-363D-11E5-9242-09173F13E4C5 n7:271B4AA9-363D-11E5-9242-09173F13E4C5 n7:271B4AAA-363D-11E5-9242-09173F13E4C5 n7:271B4AA7-363D-11E5-9242-09173F13E4C5 n7:271B4AA8-363D-11E5-9242-09173F13E4C5 n7:271B4AA4-363D-11E5-9242-09173F13E4C5 n7:271B4AA5-363D-11E5-9242-09173F13E4C5 n7:271B4AA2-363D-11E5-9242-09173F13E4C5 n7:271B4AA3-363D-11E5-9242-09173F13E4C5 n7:271B4AB1-363D-11E5-9242-09173F13E4C5 n7:271B4AB2-363D-11E5-9242-09173F13E4C5 n7:271B4AAF-363D-11E5-9242-09173F13E4C5 n7:271B4AB0-363D-11E5-9242-09173F13E4C5 n7:271B4AAD-363D-11E5-9242-09173F13E4C5 n7:271B4AAE-363D-11E5-9242-09173F13E4C5 n7:271B4AAB-363D-11E5-9242-09173F13E4C5 n7:271B4AAC-363D-11E5-9242-09173F13E4C5 n7:271B4ADE-363D-11E5-9242-09173F13E4C5 n7:271B4ADF-363D-11E5-9242-09173F13E4C5 n7:271B4ADC-363D-11E5-9242-09173F13E4C5 n7:271B4ADD-363D-11E5-9242-09173F13E4C5 n7:271B4ADA-363D-11E5-9242-09173F13E4C5 n7:271B4ADB-363D-11E5-9242-09173F13E4C5 n7:271B4AD8-363D-11E5-9242-09173F13E4C5 n7:271B4AD9-363D-11E5-9242-09173F13E4C5 n7:271B4ACE-363D-11E5-9242-09173F13E4C5 n7:271B4ACF-363D-11E5-9242-09173F13E4C5 n7:271B4ACC-363D-11E5-9242-09173F13E4C5 n7:271B4ACD-363D-11E5-9242-09173F13E4C5 n7:271B4AC5-363D-11E5-9242-09173F13E4C5 n7:271B4ACB-363D-11E5-9242-09173F13E4C5 n7:271B4AC3-363D-11E5-9242-09173F13E4C5 n7:271B4AC4-363D-11E5-9242-09173F13E4C5 n7:271B4AD6-363D-11E5-9242-09173F13E4C5 n7:271B4AD7-363D-11E5-9242-09173F13E4C5 n7:271B4AD4-363D-11E5-9242-09173F13E4C5 n7:271B4AD5-363D-11E5-9242-09173F13E4C5 n7:271B4AD2-363D-11E5-9242-09173F13E4C5 n7:271B4AD3-363D-11E5-9242-09173F13E4C5 n7:271B4AD0-363D-11E5-9242-09173F13E4C5 n7:271B4AD1-363D-11E5-9242-09173F13E4C5
n3:patent
n20:6500454
n3:routeOfElimination
Propranolol is extensively metabolized with most metabolites appearing in the urine.
n3:synonym
β-Propranolol 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol Propranolol Propranololo Propanolol beta-Propranolol Propanalol Propranololum 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
n3:toxicity
Symptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm. LD<sub>50</sub>=565 mg/kg (orally in mice).
n3:volumeOfDistribution
* 4 L
n18:hasAHFSCode
n21:24-24-00
n3:foodInteraction
Avoid alcohol. Take with food. Avoid natural licorice.
n3:mixture
n34:271B4A99-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
More than 90%
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Propranolol.htm
n13:hasConcept
n14:M0017773
foaf:page
n12:propranolol.html n25:propran.htm
n3:IUPAC-Name
n4:271B4B4A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4B50-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4B4F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4B4C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4B4D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4B4E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4B60-363D-11E5-9242-09173F13E4C5 n4:271B4B48-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4B62-363D-11E5-9242-09173F13E4C5 n4:271B4B49-363D-11E5-9242-09173F13E4C5 n4:271B4B46-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4B47-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4B64-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n19:C07AA05
n3:H-Bond-Acceptor-Count
n4:271B4B56-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4B57-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4B51-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4B52-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4B54-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4B53-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4B55-363D-11E5-9242-09173F13E4C5
n3:absorption
Propranolol is almost completely absorbed from the GI tract; however, plasma concentrations attained are quite variable among individuals.
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n4:271B4B63-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
525-66-6
n3:category
n3:containedIn
n5:271B4B20-363D-11E5-9242-09173F13E4C5 n5:271B4B2D-363D-11E5-9242-09173F13E4C5 n5:271B4B2E-363D-11E5-9242-09173F13E4C5 n5:271B4B2B-363D-11E5-9242-09173F13E4C5 n5:271B4B2C-363D-11E5-9242-09173F13E4C5 n5:271B4B29-363D-11E5-9242-09173F13E4C5 n5:271B4B2A-363D-11E5-9242-09173F13E4C5 n5:271B4B27-363D-11E5-9242-09173F13E4C5 n5:271B4B28-363D-11E5-9242-09173F13E4C5 n5:271B4B11-363D-11E5-9242-09173F13E4C5 n5:271B4B16-363D-11E5-9242-09173F13E4C5 n5:271B4B0F-363D-11E5-9242-09173F13E4C5 n5:271B4B10-363D-11E5-9242-09173F13E4C5 n5:271B4B0D-363D-11E5-9242-09173F13E4C5 n5:271B4B0E-363D-11E5-9242-09173F13E4C5 n5:271B4B0B-363D-11E5-9242-09173F13E4C5 n5:271B4B0C-363D-11E5-9242-09173F13E4C5 n5:271B4B1D-363D-11E5-9242-09173F13E4C5 n5:271B4B1E-363D-11E5-9242-09173F13E4C5 n5:271B4B1B-363D-11E5-9242-09173F13E4C5 n5:271B4B1C-363D-11E5-9242-09173F13E4C5 n5:271B4B19-363D-11E5-9242-09173F13E4C5 n5:271B4B1A-363D-11E5-9242-09173F13E4C5 n5:271B4B17-363D-11E5-9242-09173F13E4C5 n5:271B4B18-363D-11E5-9242-09173F13E4C5 n5:271B4B09-363D-11E5-9242-09173F13E4C5 n5:271B4B0A-363D-11E5-9242-09173F13E4C5 n5:271B4B07-363D-11E5-9242-09173F13E4C5 n5:271B4B08-363D-11E5-9242-09173F13E4C5 n5:271B4B05-363D-11E5-9242-09173F13E4C5 n5:271B4B06-363D-11E5-9242-09173F13E4C5 n5:271B4B04-363D-11E5-9242-09173F13E4C5 n5:271B4B14-363D-11E5-9242-09173F13E4C5 n5:271B4B15-363D-11E5-9242-09173F13E4C5 n5:271B4B12-363D-11E5-9242-09173F13E4C5 n5:271B4B13-363D-11E5-9242-09173F13E4C5 n5:271B4B33-363D-11E5-9242-09173F13E4C5 n5:271B4B34-363D-11E5-9242-09173F13E4C5 n5:271B4B31-363D-11E5-9242-09173F13E4C5 n5:271B4B32-363D-11E5-9242-09173F13E4C5 n5:271B4B2F-363D-11E5-9242-09173F13E4C5 n5:271B4B30-363D-11E5-9242-09173F13E4C5 n5:271B4B35-363D-11E5-9242-09173F13E4C5 n5:271B4B36-363D-11E5-9242-09173F13E4C5 n5:271B4B25-363D-11E5-9242-09173F13E4C5 n5:271B4B26-363D-11E5-9242-09173F13E4C5 n5:271B4B23-363D-11E5-9242-09173F13E4C5 n5:271B4B24-363D-11E5-9242-09173F13E4C5 n5:271B4B21-363D-11E5-9242-09173F13E4C5 n5:271B4B22-363D-11E5-9242-09173F13E4C5 n5:271B4B1F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4B5C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4B5E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4B5F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4B61-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4B5B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4B5A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4B5D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4B4B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4B58-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4B59-363D-11E5-9242-09173F13E4C5